摘要
医疗保障与药品行业之间的关系需要从战略购买者向战略合作者转变,医疗保障制度不仅要发挥第三方支付的功能,实现"以量换价",也要通过支持创新药的发展间接实现医疗保障制度的长期可持续发展。文章通过对部分发达国家创新药品医保政策的分析和特点总结,对我国本土创新药品医保政策的完善提出了政策建议。
The relationship between health security and the pharmaceutical industry needs to change from a strategic buyer to a strategic collaborator. The social health insurance should play not only the role of most important buyer of drugs to achieve the "price-for-value", but also should support the innovation and development of domestic drug industry. By analyzing and summarizing the characteristics of reimbursement policy for innovative drugs abroad, this article puts forward policy recommendations for the improvement of health security of domestically produced innovative drugs.
作者
鲁全
苏泽瑞
王琬
LU Quan;SU Ze-rui;WANG Wan(Social Security Research Cent-r,Renmin University of China,Beijing 100872,China;University of Internatiooal Business and Ecooomice,School of Insurance and Economics,Bejing 100029,China)
出处
《中国卫生政策研究》
CSCD
北大核心
2020年第6期1-7,共7页
Chinese Journal of Health Policy
关键词
医疗保障
本土创新药
国际经验
Health security
Domestic innovative drugs
International experience
